



News Release

Synplogen Signs Business Alliance Agreement with FUJIFILM Corporation

KOBE, Japan, March 2, 2023 - Synplogen Co., Ltd. (Head Office: Nada-ku, Kobe; President and CEO, Representative Director: Kazuhiko Yamamoto; hereinafter referred to as "Synplogen"), a biotech startup spun out of Kobe University, has entered into a business alliance agreement with FUJIFILM Corporation (Head office: Minato-ku, Tokyo; President and CEO, Representative Director: Teiichi Goto; hereinafter referred to as "Fujifilm") with the aim of further developing its custom DNA synthesis and Gene Therapy Biofoundry services.

Synplogen provides high-quality, cost-effective Gene Therapy Biofoundry services, utilizing its proprietary ultra-long and complex DNA synthesis technology. Specifically, the company provides one-stop solution services at its own R&D center in Kobe, ranging from DNA synthesis and plasmid DNA mass preparation, to viral vector design and development, production process development, characterization and quality testing, and technology transfer to GMP-compliant manufacturing facilities.

Fujifilm will utilize Synplogen's advanced plasmid DNA synthesis technology and know-how to expand the application of its contract biopharmaceutical development and manufacturing business, which is a priority business domain for the company. The company participated as a lead investor in the Series C-2 financing carried out by Synplogen on February 28, 2023.

Synplogen will continue to expand its collaboration with external partners such as Fujifilm, which have extensive experience and proven track records in GMP manufacturing of biopharmaceuticals, to further strengthen manufacturing infrastructure for gene therapy products. This will contribute to the early entry into clinical trials of gene therapy products and their early commercialization, which pharmaceutical companies and drug discovery startups are striving to develop.

About Synplogen

Synplogen Co., Ltd. is a synthetic biology startup company founded in 2017 and originated from Kobe University. Utilizing its proprietary DNA synthesis technologies, "OGAB® method" and "Combi-OGAB™ method", the company is capable of synthesizing ultra-long and complex DNA and constructing DNA libraries with various combinations. We also provide one-stop solution services from design, development, analysis to technology transfer of high-quality, cost-effective viral vectors for gene therapy at our R&D Center in Kobe, as a biofoundry specializing in gene therapy.

Head Office: 1-1 Rokkodai-cho Nada-ku, Kobe Japan
Established: February 2017
Representative: Kazuhiko Yamamoto, President and CEO, Representative Director
Capital: JPY 3,247.28 million (including capital reserve)
Business: Custom DNA synthesis and Gene Therapy Biofoundry services
URL: <https://www.synplogen.com/>

About FUJIFILM Corporation

Head Office: 9-7-3 Akasaka, Minato-ku, Tokyo
Established: October 2006
Representative: Teiichi Goto, President and CEO, Representative Director
Capital: JPY 40 billion
Business: Healthcare, Materials, and Imaging
URL: <https://www.fujifilm.com/jp/ja>

Contact:

Synplogen Co., Ltd.

Email: info@synplogen.com